DOCSLIB.ORG

Principles of Neuropsychopharmacology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Principles of Neuropsychopharmacology Principles of Neuropsychopharmacology Robert S. Feldman University of Massachusetts Jerrold S. Meyer University of Massachusetts Linda F. Quenzer University of Hartford Sinauer Associates, Inc., Publishers Sunderland, Massachusetts © Sinauer Associates, Inc. This material cannot be copied, reproduced, manufactured or disseminated in any form without express written permission from the publisher. Brief Contents Basic Concepts xxi 1. Principles of Pharmacology 1 2. Methods in Neuropsychopharmacology 27 3. Neurons and Glial Cells 75 4. Functional Neuroanatomy 111 5. Neurophysiological Mechanisms 155 6. Synaptic Structure and Function 185 Neurotransmitter Systems 233 7. Acetylcholine 235 8. Catecholamines 277 9. Serotonin 345 10. The Amino Acid Neurotransmitters and Histamine 391 11. Peptide Neurotransmitters 455 Major Drug Classes 493 12. The Opiates 495 13. Stimulants: Amphetamine and Cocaine 549 14. Stimulants: Nicotine and Caffeine 591 15. Alcohol 625 16. Sedative–Hypnotic and Anxiolytic Drugs 673 17. Mind-Altering Drugs 731 Clinical Applications 781 18. Schizophrenia 783 19. Affective Disorders 819 20. Parkinson’s Disease and Alzheimer’s Disease 861 © Sinauer Associates, Inc. This material cannot be copied, reproduced, manufactured or disseminated in any form without express written permission from the publisher. Contents BASIC CONCEPTS xxi Part II Techniques in Behavioral Pharmacology 57 Animal Care Guidelines 57 1. Principles of Pharmacology 1 New Drug Evaluation 58 Determinants of Drug Action 1 Primary Evaluation 59 Route of Administration 2 Measures of Motor Activity 59 Drug Absorption and Distribution 5 Interactions with Other Drugs 60 Effects of Age, Sex, and Body Size 6 Secondary Evaluation 60 Drug Transport across Membranes 6 Measures of Analgesia 60 Drug Binding 12 Tests of Learning and Memory 61 Depot Binding 12 Measures of Spatial Learning 63 Receptor Binding 13 Tests of Delayed Reaction 64 Law of Mass Action 13 Measures of Anxiety 65 Dose–Response Relationships 14 Schedule-Controlled Behavior 66 Side Effects and the Therapeutic Index 15 Positive Reinforcement Schedules 67 Receptor Antagonists 16 Drug Effects and Baseline Response Rate 69 Drug Inactivation and Elimination 17 Negative Reinforcement and Punishment 69 Drug Clearance 17 Drugs Used as Discriminative Stimuli 71 Drug Metabolism 17 Part II Summary 73 Renal Excretion 19 Tolerance and Sensitization 20 3. Neurons and Glial Cells 75 Cross Tolerance 21 Neuron Function 75 Drug Disposition Tolerance 21 Neuron Morphology 76 Pharmacodynamic Tolerance 22 Microanatomy of Neurons 77 Behavioral Tolerance 22 The Cell Body 77 Tolerance by Indirect Mechanisms 23 The Nucleus and Nucleolus 78 Sensitization or Reverse Tolerance 24 Mitochondria 80 Placebo Effects 24 Peroxisomes 80 Summary 25 Lysosomes and Endosomes 81 The Neuronal Cytoskeleton: Microtubules, 2. Methods in Neuropsychopharmacology 27 Neurofilaments, and Actin Filaments 81 Part I Neurochemical Techniques 28 Genetic Activity within Neurons 82 Neurotransmitter Measurement and Localization 28 DNA Strucutre 82 Histofluorescent Techniques 28 The Permanence of the Genetic Code 83 Immunocytochemistry 29 Gene Transcription 83 Autoradiography 31 Gene Translation 85 In Situ Hybridization 31 Protein Destination 87 Immunoassay Techniques 35 The Role of the Endoplasmic Reticulum 87 Colunm Chromatography 36 The Smooth Endoplasmic Reticulum and the Golgi In Vivo Microdialysis 39 Apparatus 87 Electrochemistry 41 Dendrites 88 Receptor Measurement and Localization 43 Learning and Dendritic Changes 90 Radioligand Binding 43 Axons 90 Interpretation of Ligand–Receptor Binding 43 Axon Dimensions 91 Ligand–Receptor Kinetics 46 Axonal Collaterals 92 Mathematical Transformations and Data Plotting 48 Axonal Transport 92 Receptor Autoradiography 49 The Nerve Cell Membrane 95 Receptor Isolation and Labeling 50 Membrane Structure 95 Brain Metabolism and Imaging Methods 51 Transport across Membranes 99 Enzyme Kinetics 51 Neuroglia 103 Autoradiography of Dynamic Cell Processes 52 Myelin and Myelination 104 In Vivo Imaging 54 Myelin Formation 105 Part I Summary 56 Chemical Factors in Myelination 106 © Sinauer Associates, Inc. This material cannot be copied, reproduced, manufactured or disseminated in any form without express written permission from the publisher. x Contents Nodes of Ranvier 108 Determinants and Effects of Nerve Impulse Myelin Function 108 Frequency 180 Myelin Pathology 109 Information Transmission 180 Summary 109 Refractory Periods 181 Impulse Transmission between Neurons 182 4. Functional Neuroanatomy 111 Part II Summary 184 Organization of the CNS 112 Part I The Spinal Cord, Brain Stem, Diencephalon, 6. Synaptic Structure and Function 185 Limbic System, and Basal Ganglia 113 Psychotropic Drugs and Synapses 185 Morphology of Synapses 186 The Spinal Cord 113 Synaptic Ultrastructure 187 The Brain Stem 116 Quantitative Considerations 190 The Cranial Nerves 116 Qualitative Considerations 191 The Cerebellum 119 Axoaxonic Synapses and Presynaptic Inhibition 192 The Reticular Formation 121 Neuroeffector Junctions 194 The Midbrain 122 Gap Junctions 196 The Diencephalon 125 Neurochemistry of Synaptic Transmission 197 The Thalamus 125 The Identification of Neurotransmitters 198 The Hypothalamus and Limbic System 126 The Chemical Structure of Neurotransmitters 200 The Basal Ganglia 130 Neurotransmitter Release 201 Part I Summary 132 Neurotransmitter Receptors and Signal Transduction Part II The Cerebral Cortex 132 Mechanisms 208 The Telencephalon 132 The Concept of Receptor Subtypes 208 The Cerebral Cortex 133 Receptor Superfamilies 208 Function of the Corpus Callosum 133 Structure and Mechanism of G Proteins 209 Cortical Cell Morphology 134 Direct Interactions of G Proteins with Ion Channels Organization of the Cortex 135 211 Functional Localization in the Neocortex 136 Receptor Tyrosine Kinases 212 Cortical Control of Movement 139 Second Messenger Systems 212 Language Functions of the Cerebral Cortex 142 Cyclic AMP 213 Part II Summary 144 Cyclic GMP 215 Part III The Autonomic Nervous System 144 Calcium and Calmodulin 217 The Enteric System 146 Phosphoinositide-Derived Second Messengers 219 The Parasympathetic System 146 Messenger Substances Related to Arachidonic Acid The Sympathetic System 149 221 Part III Summary 152 Divergence and Convergence of Transmitter Action 222 5. Neurophysiological Mechanisms 155 Neurotransmitters and Gene Regulation in the Part I Bioelectric Properties of Neurons 155 Nervous System 222 Neuron Excitability 155 Termination of Transmitter Action 224 The Membrane Resting Potential 156 Autoreceptors and Heteroreceptors 225 Measurement of the Resting Potential 158 Synaptic Plasticity 227 Establishment of the Resting Potential 159 Reflexive and Instinctive Behaviors 227 The Nernst Equation 161 Learning 228 Ion Involvement during Changes in Membrane Mechanisms of Synaptic Plasticity 228 Potentials 161 Summary 231 The Sodium–Potassium Pump 162 Part I Summary 163 NEUROTRANSMITTER SYSTEMS 233 Part II Action Potentials: Development, 7. Acetylcholine 235 Propagation, and Behavior 163 Part I Acetylcholine Neurochemistry: Synthesis, Determinants of Ion Permeability 163 Storage, Release, and Inactivation 235 Carrier Proteins 163 Acetylcholine Synthesis 237 Membrane Channels 164 Choline Acetyltransferase 237 Channel Gating Mechanisms 165 The Sources of Acetylcholine Precursors 237 Voltage-Gated Channels 168 Regulation of Acetylcholine Synthesis 238 The Generation and Propagation of Action Acetylcholine Storage and Release 239 Potentials 171 Miniature End-Plate Potentials 239 Passive Electrical Conduction by Neurons 171 The Source of Quantally Released Acetylcholine 240 The Generation of Electrotonic Potentials 172 Cholinergic Vesicles and Biochemical Pools of The Mechanics of Action Potentials 175 Acetylcholine 249 Propagation of the Action Potential 178 Acetylcholine Inactivation 242 © Sinauer Associates, Inc. This material cannot be copied, reproduced, manufactured or disseminated in any form without express written permission from the publisher. Contents xi Cholinesterases 242 Catecholamine Inactivation 294 Properties of Acetylcholinesterase 242 Catecholamine Uptake 294 Noncholinergic Functions of Acetylcholinesterase 244 Catecholamine Uptake Inhibitors 294 Drugs That Affect Acetylcholine Synthesis, Storage, Catabolism of Catecholamines 296 Release, and Inactivation 244 Measurement of Catecholamine Turnover 301 Drugs That Block Acetylcholine Synthesis 244 Catecholamine Neurotoxins 301 Drugs That Affect Acetylcholine Storage and Release Part I Summary 302 245 Part II Dopamine Systems: Anatomy, Physiology, Drugs That Affect Acetylcholine Inactivation 246 and Behavior 303 Part I Summary 248 Distribution of Dopamine Neurons in the Nervous Part II Anatomy and Physiology of Cholinergic System 303 Systems 249 Methods Used to Map Dopaminergic Pathways 303 Distribution of Cholinergic Neurons and Their Anatomy of Central Dopaminergic Systems 304 Connections 249 Peripheral Dopaminergic Systems 307 Cholinergic Systems within the CNS 249 Fine Structure of Dopamine Synapses: Implications for Location of Cholinergic Cell Groups and Pathways in Dopaminergic Neurotransmission 307 the Brain 249 Coexistence of Dopamine with Other Transmitters 307 Peripheral Cholinergic Systems 251 Electrophysiology of Dopaminergic Neurons 308 Acetylcholine Receptors 251 Dopamine Receptors 308 Acetylcholine Receptor Subtypes 251 The D1-Like Receptor Subfamily 309 Nicotinic Receptors 252 The D2-Like Receptor Subfamily 310 Muscarinic Receptors 256 Dopamine
Load more

Recommended publications
  • 1: Clinical Pharmacokinetics 1
    1: CLINICAL PHARMACOKINETICS 1 General overview: clinical pharmacokinetics, 2 Pharmacokinetics, 4 Drug clearance (CL), 6 Volume of distribution (Vd), 8 The half-life (t½), 10 Oral availability (F), 12 Protein binding (PB), 14 pH and pharmacokinetics, 16 1 Clinical pharmacokinetics General overview General overview: clinical pharmacokinetics 1 The ultimate aim of drug therapy is to achieve effi cacy without toxicity. This involves achieving a plasma concentration (Cp) within the ‘therapeutic window’, i.e. above the min- imal effective concentration (MEC), but below the minimal toxic concentration (MTC). Clinical pharmacokinetics is about all the factors that determine variability in the Cp and its time-course. The various factors are dealt with in subsequent chapters. Ideal therapeutics: effi cacy without toxicity Minimum Toxic Concentration (MTC) Ideal dosing Minimum Effective Concentration (MEC) Drug concentration Time The graph shows a continuous IV infusion at steady state, where the dose-rate is exactly appropriate for the patient’s clearance (CL). Inappropriate dosing Dosing too high in relation to the patient’s CL – toxicity likely Minimum Toxic Concentration (MTC) Minimum Effective Concentration (MEC) Dosing too low in relation to the Drug concentration patient’s CL – drug may be ineffective Time Some reasons for variation in CL Low CL High CL Normal variation Normal variation Renal impairment Increased renal blood fl ow Genetic poor metabolism Genetic hypermetabolism Liver impairment Enzyme induction Enzyme inhibition Old age/neonate 2 General overview Clinical Pharmacokinetics Pharmacokinetic factors determining ideal therapeutics If immediate effect is needed, a loading dose (LD) must be given to achieve a desired 1 concentration. The LD is determined by the volume of distribution (Vd).
    [Show full text]
  • Narrow Therapeutic Index
    Therapeutic Drug Monitoring Some drugs have a narrow therapeutic index, which means that there is only a small difference between the minimum effective concentrations and the minimum toxic concentrations in the blood. With such drugs, small increases in dose or in blood/serum concentrations could lead to toxic effects. Therapeutic drug monitoring may help to optimise treatment in cases where there is a firm relationship between the toxic/therapeutic effects and drug concentrations in whole blood/serum. A therapeutic interval has been defined for the drugs in the following tables. This is the minimum effective and maximum safe concentration for compliant patients, on stabilised regimens. Levels within these limits should prove satisfactory in most cases. Whole blood or serum drug concentrations are useful for determining patient compliance or for assessing whether or not: 1. adequate concentrations are being achieved or, 2. potentially toxic concentrations are being reached. Depending on clinical conditions, dosage adjustments may be needed when levels are outside the therapeutic interval. Therapeutic drug monitoring can also be useful when changes are made to other medications that could affect serum or whole blood concentrations and lead to a reduction in effectiveness or increased toxicity. Although plasma drug concentrations and the therapeutic interval are useful in evaluating drug therapy, they should not be the only criteria on which treatment is based. Always remember to treat the patient, not the level. Drug concentrations in serum or whole blood are only meaningful if the correct procedures are followed regarding the timing of specimens and selection of sample tube. It is vitally important to note the exact time the sample is taken and when each dose of the drug is given.
    [Show full text]
  • Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development
    Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development Gerlie Gieser, Ph.D. Office of Clinical Pharmacology, Div. IV Objectives • Outline the Phase 1 studies conducted to characterize the Clinical Pharmacology of a drug; describe important design elements of and the information gained from these studies. • List the Clinical Pharmacology characteristics of an Ideal Drug • Describe how the Clinical Pharmacology information from Phase 1 can help design Phase 2/3 trials • Discuss the timing of Clinical Pharmacology studies during drug development, and provide examples of how the information generated could impact the overall clinical development plan and product labeling. Phase 1 of Drug Development CLINICAL DEVELOPMENT RESEARCH PRE POST AND CLINICAL APPROVAL 1 DISCOVERY DEVELOPMENT 2 3 PHASE e e e s s s a a a h h h P P P Clinical Pharmacology Studies Initial IND (first in human) NDA/BLA SUBMISSION Phase 1 – studies designed mainly to investigate the safety/tolerability (if possible, identify MTD), pharmacokinetics and pharmacodynamics of an investigational drug in humans Clinical Pharmacology • Study of the Pharmacokinetics (PK) and Pharmacodynamics (PD) of the drug in humans – PK: what the body does to the drug (Absorption, Distribution, Metabolism, Excretion) – PD: what the drug does to the body • PK and PD profiles of the drug are influenced by physicochemical properties of the drug, product/formulation, administration route, patient’s intrinsic and extrinsic factors (e.g., organ dysfunction, diseases, concomitant medications,
    [Show full text]
  • The 5-HT6 Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus Lee A
    The 5-HT6 Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus Lee A. Dawson, Ph.D., Huy Q. Nguyen, B.S., and Ping Li, B.S. Preclinical evidence has suggested a possible role for the 5-HT6 increases in extracellular glutamate levels in both frontal receptor in the treatment of cognitive dysfunction. However, cortex and dorsal hippocampus, respectively. These effects were currently there is little neurochemical evidence suggesting the completely attenuated by infusion of tetrodotoxin but mechanism(s) which may be involved. Using the selective unaffected by the muscarinic antagonist, atropine. Here we 5-HT6 antagonist SB-271046 and in vivo microdialysis, we demonstrate for the first time the selective enhancement of have evaluated the effects of this compound on the modulation excitatory neurotransmission by SB-271046 in those brain of basal neurotransmitter release within multiple brain regions regions implicated in cognitive and memory function, and of the freely moving rat. SB-271046 produced no change in provide mechanistic evidence in support of a possible basal levels of dopamine (DA), norepinephrine (NE) or 5-HT therapeutic role for 5-HT6 receptor antagonists in the in the striatum, frontal cortex, dorsal hippocampus or nucleus treatment of cognitive and memory dysfunction. accumbens. Similarly, this compound had no effect on [Neuropsychopharmacology 25:662–668, 2001] excitatory neurotransmission in the striatum or nucleus © 2001 American College of Neuropsychopharmacology. accumbens. Conversely, SB-271046 produced 3- and 2-fold Published by Elsevier Science Inc. KEY WORDS: 5-HT6 receptor; SB-271046; Microdialysis; sma et al. 1993; Ruat et al.
    [Show full text]
  • DESCRIPTION CLINICAL PHARMACOLOGY Mechanism Of
    NDA 20-844/ Topamav Sprinkle Capsules Approved Labeling Text Version: 10/26/98 DESCRIPTION Topiramate is a sulfamate-substituted monosaccharide that is intended for use as an antiepileptic drug. TOPAMAX@ (topiramate capsules) Sprinkle Capsules are available as I5 mg, 25 mg and 50mg sprinkle capsules for oral administration as whole capsules or for opening and sprinkling onto soft food. Topiramate is a white crystalline powder with a bitter taste. Topiramate is most soluble in alkaline solutions containing sodium hydroxide or sodium phosphate and hawng a pH of 9 to IO. It is freely soluble in acetone, chloroform, dimethylsulfoxide, and ethanol. The solubility in water is 9.8 mg/mL. Its saturated solution has a pH of 6.3. Topiramate has the molecular formula C,,H,,NO,S and a molecular weight of 339.37. Topiramate is designated chemically as 2,3:4,5-Di-O-isopropylidene-~- D-fructopyranose sulfamate and has the following structural formula: H3C CH3 TOPAMAX” (topiramate capsules) Sprinkle Capsules contain topiramate coated beads in a hard gelatin capsule. The inactive ingredients are: sugar spheres (sucrose and starch), povidone, cellulose acetate, gelatin, silicone dioxide, sodium lauryl sulfate, titanium dioxide, and black pharmaceutical ink. CLINICAL PHARMACOLOGY Mechanism of Action: The precise mechanism by which topiramate exerts its antiseizure effect is unknown; however, electrophysiological and biochemical studies of the effects of topiramate on cultured neurons have revealed three properties that may contribute to topiramate’s antiepileptic efficacy. First, action potentials elicited repetitively by a sustained depolarization of the neurons are blocked by topiramate in a time-dependent manner, suggestive of a state-dependent sodium channel blocking action.
    [Show full text]
  • M100907, a Serotonin 5-HT2A Receptor Antagonist and Putative Antipsychotic, Blocks Dizocilpine-Induced Prepulse Inhibition Defic
    M100907, a Serotonin 5-HT2A Receptor Antagonist and Putative Antipsychotic, Blocks Dizocilpine-Induced Prepulse Inhibition Deficits in Sprague–Dawley and Wistar Rats Geoffrey B. Varty, Ph.D., Vaishali P. Bakshi, Ph.D., and Mark A. Geyer, Ph.D. a In a recent study using Wistar rats, the serotonergic 5-HT2 1 receptor agonist cirazoline disrupts PPI. As risperidone a receptor antagonists ketanserin and risperidone reduced the and M100907 have affinity at the 1 receptor, a final study disruptive effects of the noncompetitive N-methyl-D- examined whether M100907 would block the effects of aspartate (NMDA) antagonist dizocilpine on prepulse cirazoline on PPI. Risperidone partially, but inhibition (PPI), suggesting that there is an interaction nonsignificantly, reduced the effects of dizocilpine in Wistar between serotonin and glutamate in the modulation of PPI. rats, although this effect was smaller than previously In contrast, studies using the noncompetitive NMDA reported. Consistent with previous studies, risperidone did antagonist phencyclidine (PCP) in Sprague–Dawley rats not alter the effects of dizocilpine in Sprague–Dawley rats. found no effect with 5-HT2 antagonists. To test the hypothesis Most importantly, M100907 pretreatment fully blocked the that strain differences might explain the discrepancy in effect of dizocilpine in both strains; whereas SDZ SER 082 these findings, risperidone was tested for its ability to had no effect. M100907 had no influence on PPI by itself reduce the PPI-disruptive effects of dizocilpine in Wistar and did not reduce the effects of cirazoline on PPI. These and Sprague–Dawley rats. Furthermore, to determine studies confirm the suggestion that serotonin and glutamate which serotonergic receptor subtype may mediate this effect, interact in modulating PPI and indicate that the 5-HT2A the 5-HT2A receptor antagonist M100907 (formerly MDL receptor subtype mediates this interaction.
    [Show full text]
  • Moving Beyond Single Gene-Drug Pairs in Clinical Pharmacogenomics Testing
    Moving Beyond Single Gene-Drug Pairs in Clinical Pharmacogenomics Testing Yuan Ji, PhD, DABCP, FACMG Gwendolyn McMillin, PhD, DABCC Learning Objectives • Describe the strengths and limitations of pharmacogenomic testing. • List examples of single gene-drug associations with the strongest levels of evidence for clinical implementation. • Discuss cautions when considering the use of multi-gene drug associations to inform drug therapy decisions. 2 Disclosure • None 3 Outline • Singe gene-drug based pharmacogenomics (PGx) testing – An introduction – Evidence and examples – Considerations for developing and evaluating clinical PGx laboratory developed tests (LDTs) • Multi-gene PGx panels – Evidence and examples – PROs and CONs for utilizing PGx panels – Considerations for successful PGx implementation 4 Single Gene-Drug Based PGx Testing Yuan Ji, PhD, DABCP, FACMG Medical Director of Genomics and Genetics; PGx, ARUP Laboratories Associate Professor (Clinical) of Pathology, University of Utah Medications: Myths and Facts • are~30% peoplenot take“one at least-size one medication fits all” within a 30-day period • Most medications cause adverse drug events (ADEs) • Some medications like antibiotics may do more harm than good • CDC statistics: – ~ 200,000 ADEs-related ER visits in pediatric population (17 years or younger) – ~ 450,000 ADEs-related ER visits in older adults (65 years or older) – Medications, e.g., anticoagulant warfarin • Many ADEs are preventable by closely supervising of dosing, blood tests (therapeutic drug monitoring, TDM),
    [Show full text]
  • Early-Life Experience, Epigenetics, and the Developing Brain
    Neuropsychopharmacology REVIEWS (2015) 40, 141–153 & 2015 American College of Neuropsychopharmacology. All rights reserved 0893-133X/15 REVIEW ............................................................................................................................................................... www.neuropsychopharmacologyreviews.org 141 Early-Life Experience, Epigenetics, and the Developing Brain 1 ,1 Marija Kundakovic and Frances A Champagne* 1Department of Psychology, Columbia University, New York, NY, USA Development is a dynamic process that involves interplay between genes and the environment. In mammals, the quality of the postnatal environment is shaped by parent–offspring interactions that promote growth and survival and can lead to divergent developmental trajectories with implications for later-life neurobiological and behavioral characteristics. Emerging evidence suggests that epigenetic factors (ie, DNA methylation, posttranslational histone modifications, and small non- coding RNAs) may have a critical role in these parental care effects. Although this evidence is drawn primarily from rodent studies, there is increasing support for these effects in humans. Through these molecular mechanisms, variation in risk of psychopathology may emerge, particularly as a consequence of early-life neglect and abuse. Here we will highlight evidence of dynamic epigenetic changes in the developing brain in response to variation in the quality of postnatal parent–offspring interactions. The recruitment of epigenetic pathways for the
    [Show full text]
  • Narrow Therapeutic Index Drugs: a Clinical Pharmacological Consideration to Flecainide Juan Tamargo, Jean-Yves Le Heuzey, Phillipe Mabo
    Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide Juan Tamargo, Jean-Yves Le Heuzey, Phillipe Mabo To cite this version: Juan Tamargo, Jean-Yves Le Heuzey, Phillipe Mabo. Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. European Journal of Clinical Pharmacology, Springer Verlag, 2015, 71 (5), pp.549-567. 10.1007/s00228-015-1832-0. hal-01143095 HAL Id: hal-01143095 https://hal-univ-rennes1.archives-ouvertes.fr/hal-01143095 Submitted on 16 Apr 2015 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Eur J Clin Pharmacol (2015) 71:549–567 DOI 10.1007/s00228-015-1832-0 REVIEW ARTICLE Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide Juan Tamargo & Jean-Yves Le Heuzey & Phillipe Mabo Received: 5 December 2014 /Accepted: 4 March 2015 /Published online: 15 April 2015 # The Author(s) 2015. This article is published with open access at Springerlink.com Abstract specify flecainide as an NTID. The literature review demon- Purpose The therapeutic index (TI) is the range of doses at strated that flecainide displays NTID characteristics including which a medication is effective without unacceptable adverse a steep drug dose–response relationship for safety and effica- events.
    [Show full text]
  • Pharmacogenetic Testing: a Tool for Personalized Drug Therapy Optimization
    pharmaceutics Review Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization Kristina A. Malsagova 1,* , Tatyana V. Butkova 1 , Arthur T. Kopylov 1 , Alexander A. Izotov 1, Natalia V. Potoldykova 2, Dmitry V. Enikeev 2, Vagarshak Grigoryan 2, Alexander Tarasov 3, Alexander A. Stepanov 1 and Anna L. Kaysheva 1 1 Biobanking Group, Branch of Institute of Biomedical Chemistry “Scientific and Education Center”, 109028 Moscow, Russia; [email protected] (T.V.B.); [email protected] (A.T.K.); [email protected] (A.A.I.); [email protected] (A.A.S.); [email protected] (A.L.K.) 2 Institute of Urology and Reproductive Health, Sechenov University, 119992 Moscow, Russia; [email protected] (N.V.P.); [email protected] (D.V.E.); [email protected] (V.G.) 3 Institute of Linguistics and Intercultural Communication, Sechenov University, 119992 Moscow, Russia; [email protected] * Correspondence: [email protected]; Tel.: +7-499-764-9878 Received: 2 November 2020; Accepted: 17 December 2020; Published: 19 December 2020 Abstract: Pharmacogenomics is a study of how the genome background is associated with drug resistance and how therapy strategy can be modified for a certain person to achieve benefit. The pharmacogenomics (PGx) testing becomes of great opportunity for physicians to make the proper decision regarding each non-trivial patient that does not respond to therapy. Although pharmacogenomics has become of growing interest to the healthcare market during the past five to ten years the exact mechanisms linking the genetic polymorphisms and observable responses to drug therapy are not always clear. Therefore, the success of PGx testing depends on the physician’s ability to understand the obtained results in a standardized way for each particular patient.
    [Show full text]
  • Narrow Therapeutic Index Drugs
    Quality and Bioequivalence Standards for Narrow Therapeutic Index Drugs Lawrence X. Yu, Ph.D. Deputy Director for Science and Chemistry Office of Generic Drugs Center for Drug Evaluation and Research Food and Drug Administration GPhA 2011 Fall Technical Workshop 1 Bioequivalence • The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administrated at the same molar dose under similar conditions in an appropriately designed study…” (21 CFR §320.1) 2 Plasma Concentration Profile Cmax 10000 AUC ln Concentration 1000 Concentration Time Tmax - time of maximum concentration 100 Time 3 0 5 10 15 20 25 Possible Outcome of BE Studies Demonstrate BE Fail to Demonstrate BIE Fail to Demonstrate BE Demonstrate BIE Demonstrate BIE 80% T/R (%) 125% 4 5 FDA 12 Year BE Data Distribution of AUCt Ratios Average difference = 3.56% 10 N = 2069 8 6 Percent of Total(%) of Percent 4 2 0 0.84 0.86 0.88 0.90 0.92 0.94 0.96 0.98 1.00 1.02 1.04 1.06 1.08 1.10 1.12 1.14 1.16 1.18 1.20 6 AUC Point Estimate (T/R) Effect of Variability on BE Studies High variability 80% T/R (%) 125% 7 Development of BE Standard for Highly Variable Drugs 4/2004 First presentation to the FDA Advisory Committee 10/2006 Second presentation to the FDA Advisory Committee 3/2007 Received the first ANDA which used the new FDA BE approach 5/2007 Critical Path Opportunities for Generic Drugs BE of HVD 1/2008 FDA OGD’s first publication on BE of HVD (Pharm.
    [Show full text]
  • Immediately Dangerous to Life Or Health (IDLH) Value Profile: Butane
    Butane CAS® No. 106-97-8 DEPARTMENT OF HEALTH AND HUMAN SERVICES Center for Disease Control and Prevention National Institute of Occupational Safety and Health This page intentionally left blank. Immediately Dangerous to Life or Health (IDLH) Value Profile Butane [CAS® No. 106-97-8] H3C CH3 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational Safety and Health This document is in the public domain and may be freely copied or reprinted. Disclaimer Mention of any company or product does not constitute endorsement by the National Institute for Occupational Safety and Health (NIOSH). In addition, citations to websites external to NIOSH do not constitute NIOSH endorsement of the sponsoring organizations or their programs or products. Furthermore, NIOSH is not responsible for the content of these websites. Ordering Information To receive this document or information about other occupational safety and health topics, contact NIOSH: Telephone: 1-800-CDC-INFO (1-800-232-4636) TTY: 1-888-232-6348 E-mail: [email protected] or visit the NIOSH ebsite at: www.cdc.gov/niosh For a monthly update on news at NIOSH, subscribe to NIOSH eNews by visiting www.cdc.gov/niosh/eNews. Suggested Citation NIOSH [2016]. Immediately dangerous to life or health (IDLH) value profile: butane. By Dotson GS, Maier A, Parker A, Haber L. Cincinnati, OH: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupa- tional Safety and Health, DHHS (NIOSH) Publication 2016-174. DHHS (NIOSH) Publication No. 2016-174 September 2016 ii IDLH Value Profile for Butane Foreword Chemicals are a ubiquitous component of the modern workplace.
    [Show full text]